Dicerna Pharmaceuticals
Lexington
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $420.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2018)
- Ticker: nasdaq:DRNA
- Website: dicerna.com
- Phone: 6176126254
Industries & Categories
Biotechnology, Genetics, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/dicerna-pharmaceuticals-162448 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.